Direct
NAV (17-May-24)
Returns (Since Inception)
Fund Size
₹831 Cr
Expense Ratio
1.07%
ISIN
INF179KC1HO1
Minimum SIP
₹100
Exit Load
1.00%
Inception Date
04 Oct 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+28.22%
— (Cat Avg.)
Equity | ₹815.75 Cr | 98.20% |
Others | ₹14.92 Cr | 1.80% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹112.19 Cr | 13.51% |
Cipla Ltd | Equity | ₹65.29 Cr | 7.86% |
Lupin Ltd | Equity | ₹52.7 Cr | 6.34% |
Ajanta Pharma Ltd | Equity | ₹41.26 Cr | 4.97% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹34.7 Cr | 4.18% |
Torrent Pharmaceuticals Ltd | Equity | ₹34.12 Cr | 4.11% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹32.65 Cr | 3.93% |
Gland Pharma Ltd | Equity | ₹31.3 Cr | 3.77% |
Aurobindo Pharma Ltd | Equity | ₹27.55 Cr | 3.32% |
Alkem Laboratories Ltd | Equity | ₹26.96 Cr | 3.25% |
Metropolis Healthcare Ltd | Equity | ₹26.45 Cr | 3.18% |
Piramal Pharma Ltd | Equity | ₹26.19 Cr | 3.15% |
Fortis Healthcare Ltd | Equity | ₹24.27 Cr | 2.92% |
Thyrocare Technologies Ltd | Equity | ₹22.49 Cr | 2.71% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹21.95 Cr | 2.64% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹20.22 Cr | 2.43% |
Pfizer Ltd | Equity | ₹18.88 Cr | 2.27% |
Global Health Ltd | Equity | ₹17.13 Cr | 2.06% |
Suven Pharmaceuticals Ltd | Equity | ₹16.17 Cr | 1.95% |
Divi's Laboratories Ltd | Equity | ₹16.01 Cr | 1.93% |
Ipca Laboratories Ltd | Equity | ₹15.75 Cr | 1.90% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹15.63 Cr | 1.88% |
Treps - Tri-Party Repo | Cash - Repurchase Agreement | ₹14.72 Cr | 1.77% |
Ami Organics Ltd | Equity | ₹13.71 Cr | 1.65% |
Jubilant Pharmova Ltd | Equity | ₹13.15 Cr | 1.58% |
Wockhardt Ltd | Equity | ₹13.15 Cr | 1.58% |
Advanced Enzyme Technologies Ltd | Equity | ₹12 Cr | 1.44% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.75 Cr | 1.41% |
Vijaya Diagnostic Centre Ltd | Equity | ₹10.97 Cr | 1.32% |
Syngene International Ltd | Equity | ₹9.99 Cr | 1.20% |
Medplus Health Services Ltd | Equity | ₹9.5 Cr | 1.14% |
Medi Assist Healthcare Services Ltd | Equity | ₹8.24 Cr | 0.99% |
Unichem Laboratories Ltd | Equity | ₹8.05 Cr | 0.97% |
Indoco Remedies Ltd | Equity | ₹5.38 Cr | 0.65% |
Net Current Assets | Cash | ₹0.2 Cr | 0.02% |
Large Cap Stocks
27.40%
Mid Cap Stocks
29.14%
Small Cap Stocks
41.66%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹790.04 Cr | 95.11% |
Basic Materials | ₹25.71 Cr | 3.09% |
Standard Deviation
This fund
--
Cat. avg.
14.57%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.69
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.16
Higher the better
Since October 2023
Since October 2023
ISIN | INF179KC1HO1 | Expense Ratio | 1.07% | Exit Load | 1.00% | Fund Size | ₹831 Cr | Age | 04 Oct 2023 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | S&P BSE Healthcare TR INR |
---|
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹13.07 Cr | 54.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹694.50 Cr | 57.4% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹694.50 Cr | 55.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹36.50 Cr | 52.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹161.86 Cr | 48.4% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹161.86 Cr | 45.4% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2236.01 Cr | 52.1% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2236.01 Cr | 49.9% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹639.49 Cr | 53.9% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹16.41 Cr | 51.7% |
Total AUM
₹5,87,828 Cr
Address
“HUL House”, 2nd Floor, Mumbai, 400 020
Your principal amount will be at Very High Risk